Some clinical trials have also explored the effect of lipid-modifying drugs on cancer risk; for example, a phase 3 clinical trial that was designed to assess the clinical efficacy and safety of anacetrapib [cholesteryl ester transfer protein [CETP] inhibitor] has reported a slightly increased but not significant risk of genitourinary cancer [relative risk [RR]: 1.08, 95% CI: 0.93–1.27] (12). This evidence concerns the gene CETP and urogenital neoplasm.